|
| Status |
Public on Jan 14, 2013 |
| Title |
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
17 patients with myelofibrosis contributed paired research samples; the time points were pre-study and 12 weeks after commencing study treatment with CYT387.Gene expression analysis was investigated to study the effects of drug treatment. Additional analysis invesitigated differences in expression patterns in groups of anemia responders and non-responders following drug treatment.
|
| |
|
| Overall design |
34 samples representing 17 patients. Each patient submitted 1 pre-treatment sample and 1 post 12 weeks of treatment.
|
| |
|
| Contributor(s) |
Pardanani A, Laborde RR, L. Lasho T, Leontovich AA, Tefferi A |
| Citation(s) |
23459451 |
| Submission date |
Sep 12, 2012 |
| Last update date |
Aug 13, 2018 |
| Contact name |
Animesh Pardanani |
| E-mail(s) |
pardanani.animesh@mayo.edu
|
| Organization name |
Mayo Clinic
|
| Department |
Hematology
|
| Lab |
Dr. Pardanani
|
| Street address |
200 1st St SW
|
| City |
Rochester |
| State/province |
MN |
| ZIP/Postal code |
55905 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL10558 |
Illumina HumanHT-12 V4.0 expression beadchip |
|
| Samples (34)
|
|
| Relations |
| BioProject |
PRJNA175066 |
Less...
More...